1. Home
  2. LUCY vs ENSC Comparison

LUCY vs ENSC Comparison

Compare LUCY & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innovative Eyewear Inc.

LUCY

Innovative Eyewear Inc.

HOLD

Current Price

$1.71

Market Cap

5.3M

Sector

Health Care

ML Signal

HOLD

Logo Ensysce Biosciences Inc.

ENSC

Ensysce Biosciences Inc.

HOLD

Current Price

$1.06

Market Cap

6.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LUCY
ENSC
Founded
2017
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3M
6.3M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
LUCY
ENSC
Price
$1.71
$1.06
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
8.9M
452.9K
Earning Date
11-13-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,392,547.00
$4,487,973.00
Revenue This Year
$80.76
N/A
Revenue Next Year
$210.34
N/A
P/E Ratio
N/A
N/A
Revenue Growth
53.22
1.51
52 Week Low
$0.95
$0.86
52 Week High
$6.87
$8.97

Technical Indicators

Market Signals
Indicator
LUCY
ENSC
Relative Strength Index (RSI) 62.90 35.31
Support Level $1.36 $0.89
Resistance Level $2.00 $1.10
Average True Range (ATR) 0.13 0.09
MACD 0.05 0.02
Stochastic Oscillator 71.72 44.72

Price Performance

Historical Comparison
LUCY
ENSC

About LUCY Innovative Eyewear Inc.

Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: